AIM: For the diagnosis of osteochondritis dissecans (OD) MRI is used besides X-ray. However, there is no consensus about the necessity of MRI or the interpretation of MRI. The aim of this prospective study was to find a diagnostic concept for OD which is simple and practicale for daily routine. METHOD: In 90 patients with OD of the knee or ankle MRI (T1- and T2-w SE) was carried out before arthroscopy. According to the interface between the osteochondral fragment and the parent bone, MRI was classified in 2 stages ("stable" or "unstable") and compared with the arthroscopic findings. RESULTS: With the 2-stage classification of MRI, a prediction of the stability of the osteochondral fragment was possible in 92 %. Out of the 90 patients 7 (8 %) differed regarding preoperative stability in MRI compared to stability in arthroscopy. Incorrect diagnosis in MRI was only found among the patients with unstable fragments. CONCLUSION: The chosen 2-stage classification in MRI is well suitable for the planning of stage-related therapy.
AIM: For the diagnosis of osteochondritis dissecans (OD) MRI is used besides X-ray. However, there is no consensus about the necessity of MRI or the interpretation of MRI. The aim of this prospective study was to find a diagnostic concept for OD which is simple and practicale for daily routine. METHOD: In 90 patients with OD of the knee or ankle MRI (T1- and T2-w SE) was carried out before arthroscopy. According to the interface between the osteochondral fragment and the parent bone, MRI was classified in 2 stages ("stable" or "unstable") and compared with the arthroscopic findings. RESULTS: With the 2-stage classification of MRI, a prediction of the stability of the osteochondral fragment was possible in 92 %. Out of the 90 patients 7 (8 %) differed regarding preoperative stability in MRI compared to stability in arthroscopy. Incorrect diagnosis in MRI was only found among the patients with unstable fragments. CONCLUSION: The chosen 2-stage classification in MRI is well suitable for the planning of stage-related therapy.
Authors: Antoine Denis; Sami Chergui; Shuaa Basalom; Philippe M Campeau; Chantal Janelle; Thierry Pauyo Journal: Mol Genet Genomic Med Date: 2021-12-10 Impact factor: 2.183